STAAR Surgical (STAA) Insider Fang Buys 11,145 Shares

On June 18, 2026, Wang Christopher Min Fang bought 11,145 shares of STAAR Surgical Company, trading on the NasdaqGM under the ticker STAA. This insider transaction did not involve a planned purchase, indicating a personal decision to increase holdings in the company.

Insider Buying and Selling at STAAR Surgical Company

Wang Christopher Min Fang's recent acquisition of 11,145 shares is part of a series of insider transactions at STAAR Surgical on June 18, 2026. Other notable transactions include Jiang Wei selling 10,683 shares and buying 6,182 shares, Richard Lebuhn purchasing 11,145 shares, Arthur Butcher acquiring 3,709 shares, and Lou Silverman selling 10,683 shares. None of these transactions were planned, suggesting individual strategic decisions.

Other Institutional Activity in STAAR Surgical

Several institutional investors have also made changes to their STAAR Surgical holdings. Broadwood Capital Inc increased its stake by 1,104,351 shares, now holding 16,123,842 shares valued at about $301.5 million, marking a 7.4% increase. Yunqi Capital Ltd also boosted its holdings by 750,000 shares to a total of 3,257,130 shares, worth approximately $60.9 million, reflecting a 29.9% increase. On the other hand, BlackRock, Inc. reduced its position by 694,217 shares, bringing its total to 6,666,118 shares valued at around $124.7 million, a 9.4% decrease.

STAAR Surgical Company Stock Up 36.2%

Shares of NasdaqGM:STAA traded near $28.36 on Wednesday. STAAR Surgical Company, with a market capitalization of roughly $1.44 billion, has a forward P/E ratio of 29.19 and a beta of 1.234. The stock's 52-week range shows a low of $15.59 and a high of $35.87. Its 50-day moving average is $28.33, while the 200-day moving average is $24.39. The company maintains a strong financial position with a current ratio of 5.122 and a quick ratio of 4.092.

Analysts Set New Price Targets

Analysts have been active in evaluating STAAR Surgical. On May 15, 2026, Wells Fargo maintained a hold rating with a price target of $25. Canaccord Genuity, on May 14, 2026, maintained a buy rating with a target of $32. Piper Sandler, Stifel, and Mizuho all maintained hold ratings with targets of $33, $31, and $27, respectively. Wedbush upgraded the stock to a buy with a target of $40. The consensus among analysts suggests a target mean price of $29.67, based on nine opinions.

About STAAR Surgical

STAAR Surgical Company, headquartered in Lake Forest, California, operates in the healthcare sector, specifically within the medical instruments and supplies industry. The company designs, develops, and sells implantable lenses and delivery systems for eye surgeries. Its products are used to treat various visual disorders, including myopia and astigmatism. Led by CEO Ms. Deborah J. Andrews, STAAR Surgical employs 921 people and serves healthcare providers worldwide, using both direct sales and distributors.

Bottom Line

Wang Christopher Min Fang's insider purchase of STAAR Surgical shares suggests confidence in the company's future. Institutional activity shows mixed strategies, with some funds increasing their positions while others reduce theirs. Analysts provide a range of price targets, reflecting diverse opinions on the stock's potential. As always, remember that insider and institutional transactions are backward-looking and may not reflect current positions or future performance.